Ultragenyx Pharmaceutical Inc.

RARE - CIK 0001515673

Market cap$2.25 B

Rank#2019

SEC filings1,100

Ultragenyx Pharmaceutical Inc. trades as RARE and has a market capitalization of $2.25 B, making it the #2019 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $673.00M, up 20.2% from the prior year and net income of -$575.00M. This page tracks Ultragenyx Pharmaceutical Inc. through 1,100 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$673.00MFY 2025

Net income (latest FY)-$575.00MFY 2025

Operating cash flow (latest FY)-$466.00MFY 2025

Total assets (latest FY)$1.53BFY 2025

Net margin-85.4%latest FY

Financial performance

Over the last 9 fiscal years Ultragenyx Pharmaceutical Inc.'s revenue grew from $133.00K to $673.00M, a compound annual growth rate of 158.0%. Net profit margin expanded from -184867.7% to -85.4% over the same period - every figure below comes from the company's audited annual filings.

RARE annual revenueView details

Key statistics

Market cap: $2.25 B
Share price (derived)market cap / shares outstanding: $22.81
EPS (diluted)FY 2025: $-5.83
Shares outstandingas of 2026-05-01: 0.10B
Total equityas of 2025-09-30: $9.16M
Return on equity: -6278.0%
Cash & equivalentsas of 2026-03-31: $175.00M
Current ratioas of 2026-03-31: 2.02

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18

Browse the full filing history (1,100 filings)

Recent press releases

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2026-05-22
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)—Ultragenyx Pharmaceutical Inc.
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference2026-05-06
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference—Ultragenyx Pharmaceutical Inc.
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update2026-05-05
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update2026-04-29
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update—Ultragenyx Pharmaceutical Inc.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2026-04-24
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)—Ultragenyx Pharmaceutical Inc.

Similar companies

The largest companies sharing Ultragenyx Pharmaceutical Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T RARE vs LLY

JNJJohnson & Johnson$573.98 B RARE vs JNJ

ABBVAbbVie Inc.$399.47 B RARE vs ABBV

MRKMerck & Co., Inc.$293.16 B RARE vs MRK

AZNAstraZeneca PLC$286.27 B RARE vs AZN

Frequently asked questions

What is Ultragenyx Pharmaceutical Inc.'s market cap?

Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of $2.25 B as of 2026-06-10, ranking #2019 among US-listed companies.

How much revenue does Ultragenyx Pharmaceutical Inc. make?

Ultragenyx Pharmaceutical Inc. reported revenue of $673.00M for fiscal year 2025, an increase of 20.2% year over year.

Is Ultragenyx Pharmaceutical Inc. profitable?

In its latest fiscal year Ultragenyx Pharmaceutical Inc. reported a net loss of $575.00M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.